[ad_1] RT @ThomasCiullaMD: Looking forward to presenting at Medicine 2042! https://t.co/t233EJFZV0 The next two decades will be filled with new in… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @RetinalPhys: NEW PRODUCT APPLICATIONS: Xipere Suprachoroidal Injection for Uveitis https://t.co/KB1AAkjpXf https://t.co/Iith6KJ0Xl [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Looking forward to presenting at Medicine 2042! https://t.co/t233EJFZV0 The next two decades will be filled with new innovations in sustained release technology, drug delivery, gene & cell therapy, which will benefit those with untreatable genetic and chronic diseases. https://t.co/e2zo8iDszU
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Looking forward to presenting “The #Suprachoroidal Space and Suprachoroidal Delivery for Clinicians” at INNOVATE RETINA, hosted by Stanford Medicine/Byers Eye Institute on Sat, June 4! Please join virtually! Complimentary registration: https://t.co/FI3EQzPVDC #eye #retina #AMD https://t.co/QIRJiFXzRv [ad_2] Source by Thomas Ciulla, MD, MBA Return to …
[ad_1]
Just published: https://t.co/iavHrQFgR9 “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, and RVO Macular Edema: Clinical Outcomes in 130,247 Eyes”.
More effective and longer acting therapies are needed for these leading causes of legal blindness.
#eyes #retina https://t.co/roratuqzkp
[ad_2]
Source by Thomas Ciulla, MD, MBA